Cardiopulmonary Specialist/Senior Cardiopulmonary Specialist - Remodulin/Orenitram

Liquidia slumps after US court rules for United Therapeutics in patent fight. By Thomson Reuters Sep 30, 2026 | 3:41 PM Sept 30 (Reuters) - Liquidia shares plunged nearly 50% on Wednesday after a federal judge ruled that its lung drug infringes key patent held by rival United Therapeutics, dealing a major blow to the treatment's commercial outlook. The US District Court for the District of Delaware found that Liquidia's dry-powder drug, Yutrepia, infringed two foundational claims of United Therapeutics' '327 patent. The patent covers methods of treating pulmonary hypertension-associated interstitial lung disease, or PH-ILD, using inhaled treprostinil and certain dry-powder delivery features. In a related order, the court denied Liquidia's motion to throw out evidence regarding United Therapeutics' patent ownership, ruling that Liquidia had received adequate notice before trial and failed to make timely objections. "This is a key element of the case for Liquidia, and denial of the motion to strike has negative readthrough to the final decision on the case," said Raymond James analyst Ryan Deschner. The decision strengthens legal protections for United Therapeutics' blockbuster inhalation treatment, Tyvaso. Its shares jumped 12.3% to $540.54 on the ruling. Leerink Partners analysts said the court ruling gives United Therapeutics what looks like a "'win', essentially" by confirming that Yutrepia infringes a "valid UTHR patent." While, RBC Capital Markets analyst Lisa Walter said it "significantly clouds the path" for Yutrepia to compete. "We respectfully disagree with the court's decision... and are fully prepared to pursue all available appellate options," Liquidia CEO Roger Jeffs said in a statement. Liquidia, Jeffs said, plans to ask the US FDA to remove the PH-ILD indication from Yutrepia's label. Shares of Liquidia hit their lowest level in nearly four months, putting the company on track to lose about $3.18 billion from its market value, if losses hold. A final judgment is expected in about a week, analysts said. (Reporting by Christy Santhosh and Kamal Choudhury in Bengaluru; Editing by Shilpi Majumdar)

Helicopter Museum honors hydrogen-powered flight team. WEST CHESTER, PA - The American Helicopter Museum and Education Center (AHMEC) is excited to announce that it has selected the team from United Therapeutics subsidiary Unither Bioélectronique and Robinson Helicopter Company to receive the 2026 AHMEC Achievement Award. The award recognizes the team's historic first flight of a piloted, hydrogen-powered helicopter - a significant milestone in the development of zero-emission vertical flight. The achievement involved replacing the conventional Lycoming engine in a Robinson R44 helicopter with a hydrogen fuel-cell system, a lithium-ion battery pack to provide additional power when needed, and an electric motor. According to Mikaël Cardinal, Vice President of Program Management at Unither Bioélectronique, approximately 90 percent of the energy used during the flight was supplied by the hydrogen fuel cells. Martine Rothblatt, Ph.D., Chairperson and Chief Executive Officer of United Therapeutics has been a driving force behind the development of sustainable aviation technologies and is a past recipient of the AHMEC Achievement Award for her leadership in the development of the R44 electric-powered helicopter. "Every year, we solicit nominations for the AHMEC Achievement Award, and this year it was evident that the hydrogen-powered helicopter team was the clear choice," said Dan Newman, Chairman of AHMEC's Board of Trustees. "We are proud to recognize this remarkable achievement and present the award during the museum's 30th anniversary celebration on October 18, 2026." Established in 2009, the AHMEC Achievement Award is presented annually by the Museum's Board of Trustees to an individual or organization that has made a significant contribution to the advancement of vertical flight during the preceding year. Discover more Newspapers Geographic Reference Marc Sheffler, Past Chairman of the Board of Trustees and Chair of the Achievement Award Committee, noted that Unither Bioélectronique and Robinson Helicopter Company join an impressive group of past award recipients, including the AeroVelo human-powered helicopter team, the Mars Ingenuity helicopter team, and Jeff Bezos for Amazon Prime Air. The 2026 AHMEC Achievement Award will be presented during a ceremony at the American Helicopter Museum and Education Center on October 18, 2026, as part of the museum's 30th anniversary celebration. Discover more City & Local Guides Demographics Newspapers About the American Helicopter Museum and Education Center The American Helicopter Museum and Education Center, located at 1220 American Boulevard in West Chester, Pennsylvania, is the nation's premier aviation museum devoted exclusively to rotary-wing flight. Established in 1996, the nonprofit organization collects, preserves, restores, and displays historic rotorcraft, including more than 35 civilian and military helicopters, autogyros, and convertiplanes. Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources - free for everyone. If you value that, click here to become a patron today.

Merrimack Anheuser-Busch property purchased by United Therapeutics Corporation. The 300-acre property off DW Highway became available after the plant closed. The biotech firm currently has a location in Manchester. September 6, 2026 By Jeffrey Hastings Biotechnology firm United Therapeutics Corporation has acquired the former Anheuser-Busch brewery site in Merrimack for $47 million, according to sources familiar with the matter. The transaction secures one of Southern New Hampshire's largest industrial parcels, spanning nearly 300 acres off Daniel Webster Highway. The sale follows Anheuser-Busch's previous announcement that it would close the longtime facility at 221 Daniel Webster Highway as part of a nationwide restructuring of its supply chain network. The Merrimack Anheuser-Busch property purchased by United Therapeutics Corporation, they currently have a location in Manchester also. (Jeffrey Hastings). Positioned between Route 3 and the Merrimack River near the Nashua line, the sprawling site featured a massive industrial brewing operation, distribution hub infrastructure, tasting room and beer garden spaces, and stables that once housed the iconic Budweiser Clydesdales. The acquisition marks a major transition for a site that served as a local industrial centerpiece for decades. The facility had a town valuation of $35 million and generated more than $780,000 annually in local property taxes. In addition, the brewery was historically one of Merrimack's largest municipal wastewater utility users, contributing between $1 million and $1.5 million in annual utility fees. United Therapeutics is expected to bring hundreds of high-paying jobs to the region, drawing specialized talent from across the United States. Specific construction plans, architectural designs, and a timeline for redeveloping the vast industrial campus have not yet been disclosed. Silver Spring, Maryland-based United Therapeutics was founded in 1996 by Martine Rothblatt. The public benefit corporation specializes in developing therapies for rare, chronic conditions - most notably Pulmonary Arterial Hypertension (PAH). Its commercial product portfolio includes Tyvaso, Remodulin, Orenitram, Adcirca, and Unituxin. Beyond pharmaceuticals, the company is an industry pioneer in bioengineered organ manufacturing, gene-edited porcine organ transplant technologies (xenotransplantation), and 3D bioprinting designed to address the global organ shortage. The purchase represents a substantial expansion of the company's New Hampshire footprint. United Therapeutics currently operates a facility on Commercial Street in Manchester. It previously explored buying a large property off Hackett Hill Road near the Manchester-Hooksett town line, but ultimately opted not to complete the transaction.